Therapeutically, under the premise of a clear consensus on the biological function and mechanism of Reg proteins, there are two potential avenues: first, leveraging the tissue repair capacity of Reg protein by developing agonists or recombinant protein drugs, with careful removal of immunogenic elements; second, addressing their role in promoting tumor progression and autoimmune disorders by designing antibodies, inhibitors, or gene therapies to mitigate its detrimental effects. Here, REG1A is linked to neoplasm.